医药导报2023，Vol.42Issue(12)：1868-1872,5.DOI:10.3870/j.issn.1004-0781.2023.12.021
奈玛特韦/利托那韦治疗心脏移植术后感染COVID-19患者的药学监护
Pharmaceutical Care of Patients Infected with COVID-19 after Heart Transplantation Treated with Paxlovid
许璐 1陈锦华1
作者信息
- 1. 武汉亚洲心脏病医院药学部,武汉 430022
- 折叠
摘要
Abstract
Objective To evaluate the effect of pharmaceutical care provided by clinical pharmacists during the administration of Paxlovid for the treatment of COVID-19 in heart transplant patients.Methods During the treatment of COVID-19 with Paxlovid in 3 heart transplant patients,the clinical pharmacist provided pharmaceutical care in terms of the medicine indication,dosage,drug adjustment,drug interaction,adverse reaction etc,to develop individualised dosing regimens for patients.Results Clinical pharmacists are active in anticipating,identifying and resolving problems with Paxlovid in heart transplant patients,and monitoring the medication process to assist doctors in solving difficult problems.Conclusion Clinical pharmacists have explored the pharmaceutical monitoring methods for heart transplant patients during the use of Paxlovid to ensure the patients'safety and efficacy of patient medication and to improve the clinical cure rates.关键词
奈玛特韦/利托那韦/心脏移植/新型冠状病毒感染/药学监护Key words
Paxlovid/Heart transplantation/COVID-19/Pharmaceutical care分类
医药卫生引用本文复制引用
许璐,陈锦华..奈玛特韦/利托那韦治疗心脏移植术后感染COVID-19患者的药学监护[J].医药导报,2023,42(12):1868-1872,5.
